Skip to content
ContentLora

    Tip: press / anywhere to search.

    Analysis

    Who gets GLP-1 drugs? The 2026 price and coverage debate

    GLP-1 drugs work, but WHO projects they will reach fewer than 10% of people who could benefit by 2030.[1] In 2025–2026 US prices fell through a White House agreement, a temporary $50 Medicare benefit and negotiated Medicare prices. Whether that is enough, and who should pay, is contested.[2][3][4]

    Editor reviewedStrict sourcingUpdated GLP-1 and metabolic medicineHealth and medicineTech policy
    Show:

    GLP-1 medicines produce large average weight loss in trials, but they are expensive and may need to be taken long-term.[5][2][6] This page sets out the evidence on access as of October 2026 and three competing views of where it is heading.

    What the evidence shows

    List prices were high. The White House said Ozempic and Wegovy listed at about $1,000 and $1,350 a month before its November 2025 agreement.[2] Under that agreement, Medicare prices for Ozempic, Wegovy, Mounjaro and Zepbound were set at $245 a month with a $50 copay, and TrumpRx prices for Ozempic and Wegovy at $350.[2] Starting doses of future GLP-1 pills were set at about $150 a month.[7]

    Separately, Medicare’s statutory negotiation set a 30-day price of $274 for Ozempic, Rybelsus and Wegovy, against a $959 list price, effective 1 January 2027.[4] CMS’s GLP-1 Bridge, a time-limited demonstration, has offered certain GLP-1s to eligible Part D enrollees for $50 a month since 1 July 2026, running to 31 December 2027.[3] Novo says it covers a majority of beneficiaries.[8]

    Supply has eased. The FDA declared the tirzepatide and semaglutide shortages resolved in December 2024 and February 2025.[9][10] In April 2026 it proposed excluding semaglutide, tirzepatide and liraglutide from the list of substances outsourcing facilities may compound from bulk.[11] Makers report lower realised prices offset by volume: Lilly’s worldwide realised prices fell 13% in the second quarter of 2026 while volume rose 60%.[12] Novo cites loss of semaglutide exclusivity in Canada and some other markets.[13]

    Value questions remain. A 2026 German model estimated tirzepatide for obesity-related heart failure with preserved ejection fraction at about EUR 252,611 per quality-adjusted life year at current prices.[14] Weight and cardiometabolic gains tend to reverse after stopping, which pushes toward long-term use and long-term cost.[15] Globally, WHO projects GLP-1s will reach fewer than 10% of those who could benefit by 2030.[1] In September 2026 Lilly pledged to treat as many people with its diabetes and obesity medicines in resource-limited settings, including low- and middle-income countries, as in high-income countries before 2040.[16]

    How to read it

    The US has moved from a shortage-and-compounding problem in 2022–2024 to a price-and-eligibility problem. The policy tools are layered and temporary: an executive agreement, a demonstration that ends in 2027, and statutory negotiation that starts in 2027. Coverage rules could change again after 2027. The companies’ filings suggest a strategy of accepting lower unit prices for higher volume.[3][12]

    Outside the US, patent expiry is the bigger lever. Where semaglutide has lost exclusivity, Novo reports lower prices with stable volumes. That pattern could repeat in more markets.[13] Cost-effectiveness depends heavily on price and indication. A drug can be good value for one group and poor value for another at the same price.[14]

    What to watch

    Key signals over the next year: uptake and cost data from Medicare’s Bridge; what replaces it after December 2027; the FDA’s final decision on the 503B compounding proposal; generic semaglutide entry in more countries; and whether pills priced near $149 a month expand use beyond people who can afford injectables. Each of these is uncertain, and new legislation or court rulings could change the picture.[3][11][17]

    Competing views

    Price is still the main barrier

    Even after cuts, the drugs may need to be taken long-term, and health-economic models find them poor value at current prices for some uses. Access will stay narrow until prices fall much further or generics arrive.[1][14][15]

    Access is expanding quickly

    Government deals, Medicare's Bridge and pills priced from about $149 a month have widened access, and makers are trading lower prices for much higher volume.[3][17][12][18]

    Competition and patent expiry will do the work

    Loss of semaglutide exclusivity in some markets, new entrants and oral small molecules will push prices down more than policy alone.[13][19][20]

    Questions readers ask

    How much does Medicare charge for GLP-1 obesity drugs in 2026?

    Under CMS's temporary GLP-1 Bridge, eligible Part D enrollees can get certain GLP-1 medicines for $50 a month from 1 July 2026 to 31 December 2027.[3]

    What was the November 2025 White House deal?

    Lilly and Novo agreed to Medicare prices of $245 a month for Ozempic, Wegovy, Mounjaro and Zepbound, with a $50 copay for beneficiaries, and to TrumpRx prices of $350 for Ozempic and Wegovy.[2]

    Can pharmacies still compound semaglutide or tirzepatide?

    The FDA declared both shortages resolved, in December 2024 and February 2025. In April 2026 it proposed barring outsourcing facilities from compounding these drugs from bulk ingredients.[9][10][11]

    Is generic semaglutide available?

    Novo Nordisk reports that semaglutide has lost exclusivity in Canada and certain other international markets. In the US, a Medicare-negotiated price takes effect in 2027.[13][4]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      WHO projects that even with expanded production, GLP-1 therapies will reach fewer than 10% of those who could benefit by 2030. confirmedas of 2025-12-01

    2. [2]

      Under a 6 November 2025 agreement announced by the White House with Eli Lilly and Novo Nordisk, Medicare prices for Ozempic, Wegovy, Mounjaro and Zepbound were set at $245 a month with a $50 monthly copay for beneficiaries, and Ozempic and Wegovy at $350 through the TrumpRx website. confirmedas of 2025-11-06

    3. [3]

      CMS's Medicare GLP-1 Bridge, a time-limited demonstration, gives eligible Part D enrollees certain GLP-1 medicines for $50 a month from 1 July 2026 through 31 December 2027. confirmedas of 2026-05-06

    4. [4]

      Under the Medicare Drug Price Negotiation Program, CMS set a negotiated 30-day price of $274 for Ozempic, Rybelsus and Wegovy, against a 2024 list price of $959, effective 1 January 2027. confirmedas of 2025-11-25

    5. [5]

      In SURMOUNT-1, which enrolled 2,539 adults with obesity or overweight and no diabetes, weekly tirzepatide produced mean weight changes of -15.0%, -19.5% and -20.9% at doses of 5, 10 and 15 mg at 72 weeks, versus -3.1% with placebo. confirmedas of 2022-06-04

    6. [6]

      One year after stopping semaglutide and lifestyle intervention in the STEP 1 extension, participants had regained about two-thirds of their prior weight loss, and most cardiometabolic improvements reverted toward baseline. confirmedas of 2022-05-19

    7. [7]

      The November 2025 agreement set the starting dose of future oral GLP-1 drugs from the two companies at about $150 a month through TrumpRx. confirmedas of 2025-11-06

    8. [8]

      Novo Nordisk reported that the Bridge programme began on 1 July 2026 and covers a majority of Medicare beneficiaries, and Lilly reported Foundayo and Zepbound coverage under it. confirmedas of 2026-08-05

    9. [9]

      The FDA determined on 19 December 2024 that the US shortage of tirzepatide injection had been resolved. confirmedas of 2024-12-19

    10. [10]

      The FDA determined on 21 February 2025 that the US shortage of semaglutide injection products was resolved, ending temporary leeway for compounders to make copies after set grace periods. confirmedas of 2025-02-21

    11. [11]

      On 30 April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, which would bar outsourcing facilities from compounding them from bulk ingredients; comments were accepted until 29 June 2026. confirmedas of 2026-04-30

    12. [12]

      Lilly reported that in the second quarter of 2026 its worldwide revenue rose on a 60% volume increase partly offset by a 13% decrease in realised prices, with US price declines driven mainly by Zepbound and Mounjaro. confirmedas of 2026-08-05

    13. [13]

      Novo Nordisk reported that loss of exclusivity for semaglutide in Canada and certain other international markets, together with the US most-favoured-nation agreement, lowered its realised prices in 2026. confirmedas of 2026-08-04

    14. [14]

      A 2026 German health-economic model estimated that tirzepatide for obesity-related heart failure with preserved ejection fraction cost about EUR 252,611 per quality-adjusted life year at current prices, and concluded substantial price cuts would be needed. confirmedas of 2026-05-19

    15. [15]

      A 2026 BMJ meta-analysis of 37 studies found average weight regain of 0.4 kg per month after stopping weight-management medicines, with cardiometabolic markers projected to return to baseline within 1.4 years, faster than after behavioural programmes. confirmedas of 2026-01-07

    16. [16]

      On 28 September 2026 Lilly launched a commitment aiming to treat as many people with its diabetes and obesity medicines in resource-limited settings, including low- and middle-income countries, as in high-income countries before 2040. confirmedas of 2026-09-28

    17. [17]

      At launch, Lilly's self-pay price for Foundayo started at $149 a month for the lowest dose, and STAT reported prices of up to $299 a month for patients who keep renewing, matching the Wegovy pill. reportedas of 2026-04-01

    18. [18]

      By mid-July 2026, US weekly prescriptions for the Wegovy pill exceeded 265,000, with more than 5 million prescriptions since launch. confirmedas of 2026-08-04

    19. [19]

      Pfizer completed its acquisition of obesity-drug developer Metsera on 13 November 2025 at about $7.0 billion enterprise value plus contingent payments tied to its monthly injectable GLP-1 candidate MET-097i and amylin analogue MET-233i. confirmedas of 2025-11-13

    20. [20]

      Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist taken by mouth once daily. confirmedas of 2026-10-10

    Revision history (2)
    1. Page created.
    2. Refresh: added Lilly's September 2026 access commitment for low- and middle-income countries.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "Who gets GLP-1 drugs? The 2026 price and coverage debate." ContentLora, updated Oct 10, 2026. https://contentlora.com/analysis/glp-1-access-and-pricing-debate

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    ☰ Contents